Factor This Power Engineering
Live Events
DTECH⢠Events
POWERGEN®
Calendar
Resource Center
Webinars
Podcasts
White Papers
Contribute Content
Solar
Utility Scale
Community
Residential
Wind Power
Turbines & Equipment
Offshore
Power Grid
Transmission
Outage Management
Grid Modernization
Smart Grids
Microgrids
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Pumped Storage
Long Duration
Business
Policy & Regulation
Project Development
Finance
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Utility Scale
Community
Residential
Wind Power
Turbines & Equipment
Offshore
Power Grid
Transmission
Outage Management
Grid Modernization
Smart Grids
Microgrids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Pumped Storage
Long Duration
Business
Policy & Regulation
Finance
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Resource Center
Webinars
Podcasts
Whitepapers
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Silence Therapeutics plc
< Previous
1
2
Next >
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
February 23, 2024
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
February 05, 2024
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
December 01, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
November 14, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Present at Jefferies London Healthcare Conference
November 08, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease
November 01, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
September 26, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Participate in September Investor Conferences
September 06, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Reports Second Quarter 2023 Results
August 16, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration
July 11, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Present at the Jefferies Healthcare Conference
May 31, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Reports First Quarter 2023 Results
May 16, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration
May 04, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
May 01, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference
April 25, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera
April 04, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Present at Guggenheim’s Genomic Medicines and Rare Disease Days
March 29, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development
March 28, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Buyback siRNA Complement Assets
March 28, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results
March 15, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023
March 02, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Present at SVB Securities Global Biopharma Conference
February 08, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer
February 06, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Reports Third Quarter 2022 Results
November 10, 2022
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Present at Jefferies London Healthcare Conference
November 09, 2022
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting
November 05, 2022
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
September 29, 2022
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference
September 27, 2022
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Participate in September Investment Conferences
September 08, 2022
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.